NTRAMEDIUM SIGNALFINANCIAL10-K

NTRA shows meaningful expansion in R&D investment and operating scale alongside substantially improved cash generation despite wider operating losses.

The company appears to be in a deliberate growth investment phase, with substantially higher R&D spending suggesting significant product development initiatives or pipeline expansion. The strong improvement in operating cash flow generation despite wider losses indicates better working capital management and potentially improving underlying business fundamentals that could support the increased investment strategy.

Comparing 2026-02-27 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

NTRA demonstrated notable growth across most financial metrics, with R&D expenses growing substantially and SG&A expenses expanding meaningfully as the company scales operations. Operating losses widened as expected given the investment focus, but operating cash flow grew substantially, indicating strong cash conversion. The balance sheet strengthened considerably with assets, equity, and liabilities all expanding significantly, while interest expense declined notably, suggesting improved capital structure management during this growth phase.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-61.9%
$10.7M→$4.1M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
+59.9%
$66.4M→$106.2M

Capital expenditure jumped 59.9% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
+58.7%
$135.7M→$215.3M

Operating cash flow surged 58.7% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
+54.4%
$404.1M→$624.1M

R&D investment increased 54.4% — signals commitment to future product development, though near-term margin impact.

Inventory
Balance Sheet
+53%
$44.7M→$68.4M

Inventory surged 53% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Total Liabilities
Balance Sheet
+47.4%
$465.3M→$685.9M

Liabilities grew 47.4% — significant increase in debt or obligations, assess impact on financial flexibility.

Total Assets
Balance Sheet
+44.4%
$1.7B→$2.4B

Asset base grew 44.4% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+43.2%
$1.2B→$1.7B

Equity base grew 43.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

SG&A Expense
P&L
+39.9%
$841.3M→$1.2B

SG&A up 39.9% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Operating Income
P&L
-39.4%
-$222.3M→-$309.9M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-02-28
ADDED
As of February 20, 2026, the number of outstanding shares of the registrant s common stock, par value $0.0001 per share, was 141,731,250 .
Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as believe, may, will, estimate, continue, anticipate, design, intend, expect, could, plan, potential, predict, seek, should, would or the negative version of these words and similar expressions.
into our business operations; our ability to control our operating expenses and fund our working capital requirements; the factors that may impact our financial results, including our revenue recognition assumptions and estimates; and anticipated trends and challenges in our business and the markets in which we operate.
In oncology, we commercialize personalized blood-based DNA tests designed to optimize therapy decisions from diagnosis to survivorship.
In the women s health space, we develop and commercialize non- or minimally- invasive tests to support a range of women s health needs, from prenatal testing to hereditary cancer screening.
+7 more — sign up free →
REMOVED
As of February 21, 2025, the number of outstanding shares of the registrant s common stock, par value $0.0001 per share, was 135,186,184 .
Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or the negative version of these words and similar expressions.
In the women s health space, we develop and commercialize non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a wide range of genetic conditions, such as Down syndrome.
In oncology, we commercialize, among others, a personalized blood-based DNA test to detect molecular residual disease, or MRD, and monitor for disease recurrence across a broad range of cancer types.
Our third area of focus is organ health, where we offer tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →